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a b s t r a c t
Excessive proliferation of vascular smooth muscle cells (VSMCs) and incomplete re-endothelialization is a
major clinical problem limiting the long-term efﬁcacy of percutaneous coronary angioplasty. We tested if
dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NFE2-
related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. DMF signiﬁcantly attenuated
neointimal hyperplasia induced by balloon injury in rat carotid arteries via suppression of the G1 to S phase
transition resulting from induction of p21 protein in VSMCs. Initially, DMF increased p21 protein stability
through an enhancement in Nrf2 activity without an increase in p21 mRNA. Later on, DMF stimulated p21
mRNA expression through a process dependent on p53 activity. However, heme oxygenase-1 (HO-1) or NQO1
activity, well-known target genes induced by Nrf2, were dispensable for the DMF induction of p21 protein and
the effect on the VSMC proliferation. Likewise, DMF protected endothelial cells from TNF-α-induced apoptosis
and the dysfunction characterized by decreased eNOS expression. With knock-down of Nrf2 or NQO1, DMF
failed to prevent TNF-α-induced cell apoptosis and decreased eNOS expression. Also, CD31 expression, an
endothelial speciﬁc marker, was restored in vivo by DMF. In conclusion, DMF prevented abnormal proliferation
in VSMCs by G1 cell cycle arrest via p21 upregulation driven by Nrf2 and p53 activity, and had a beneﬁcial
effect on TNF-α-induced apoptosis and dysfunction in endothelial cells through Nrf2–NQO1 activity suggesting
that DMF might be a therapeutic drug for patients with vascular disease.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Neointimal hyperplasia and incomplete re-endothelialization are
major clinical mechanisms known to limit the long-term efﬁcacy of
percutaneous coronary angioplasty (PTCA) [1]. Although the introduc-
tion of drug-eluting stents has signiﬁcantly reduced the re-stenosis
rate compared to bare-metal stents [2,3], the incidence of late stent
thrombosis in recipients of drug-eluting stents is largely dependent on
the degree of re-endothelialization and intimal proliferation.
Dimethylfumarate (DMF) is the main active component of oral
formulations of fumaric acid esters that have been successfully
used for treating psoriasis in chronic inﬂammatory skin disease
[4]. Previous studies have demonstrated that DMF inhibits multi-
ple sclerosis by reducing inﬂammation [5,6] and increases cardi-
oprotection via activation of the NFE2-related factor 2 (Nrf2)
antioxidant pathway [7]. In addition, DMF attenuates renal ﬁbrosis
via Nrf2-mediated inhibition of transforming growth factor-β
(TGF-β)/Smad signaling and suppresses adipogenic differentiation
in 3T3-L1 preadipocytes through inhibition of STAT3 activity [8,9].
It was reported that DMF inhibited PDGF-induced proliferation
in airway smooth muscle cells through p38-heme oxygenase-1
(HO-1) [10]. However, the potential effects of DMF on vascular
injury after balloon angioplasty in vivo have not been studied.
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Neointimal hyperplasia is caused by growth factors and cyto-
kines released by platelets and leukocytes at sites of injury after
balloon angioplasty [11]. In the endothelial cell, DMF decreases
tissue factor and expression of adhesion molecules such as vascular
cell adhesion molecule-1 (VCAM-1) and intercellular adhesion
molecule-1 (ICAM-1) through the obstruction of tumor necrosis
factor-α (TNF-α)-induced nuclear entry of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB)/p65 [12]. Further-
more, the blockade of TNF-α accelerates functional endothelial
recovery after balloon angioplasty [13,14]. Therefore, we investi-
gated the effects of DMF on TNF-α mediated suppression of eNOS
and on TNF-α mediated apoptosis in endothelial cells.
Previous reports have demonstrated that Nrf2 protects against
tissue ﬁbrosis, diabetic nephropathy and non-alcoholic fatty liver,
presumably through enhancement of cellular antioxidant capacity
such as by increased NAD(P)H quinone oxidoreductase 1 (NQO1)
and heme oxygenase-1 (HO-1) [15–17]. DMF and its primary
metabolite monomethylfumarate can activate Nrf2, a well-
known Cap-N-Collar transcription factor that is essential for
antioxidant responsive element (ARE)-mediated transcription
such as for NQO1 and HO-1 [8,9]. Also, several studies have shown
that Nrf2 overexpression prevents neointimal hyperplasia by
inhibiting the proliferation of VSMCs after vascular injury through
HO-1 dependent antioxidant and anti-inﬂammatory effects
[18,19]. The beneﬁcial effect of DMF induced Nrf2–NQO1 activity
has not been reported with regard to endothelial dysfunction
occurring during abnormal vascular remodeling. Basically, we have
investigated the mechanism by which DMF could prevent abnor-
mal VSMC proliferation by modulation of the cell cycle via p21
protein upregulation through Nrf2 and p53 activity, and protect
against TNF-α-induced apoptosis and dysfunction in endothelial
cells through Nrf2–NQO1 activity, respectively.
Materials and methods
Animals
The procedures used in this study were approved by the
Animal Care and Use Committee of Kyungpook National University
School of Medicine and conducted according to the Guide for the
Care and Use of Laboratory Animals published by the United States
National Institutes of Health (NIH Publication, 8th Edition, 2011).
Ten-week-old male Sprague-Dawley (SD) rats (Hyochang, Daegu,
Korea) weighing 280–320 g were used for in vivo experiments. All
animals were provided ad libitum access to food (standard chow
diet, Research diets, New Brunswick, NJ, USA) and water before
the study.
Materials
Dimethylfumarate was purchased from Sigma-Aldrich (St.
Louis, MO, USA). The antibodies against Nrf2, Cyclin D and Cyclin
E were purchased from Santa Cruz Biotechnologies (Santa Cruz,
CA, USA). The antibodies for p21 and p27 were from BD Bioscience
(San Jose, CA, USA); antibodies for Keap1, p53, p-p53, Rb, and p-Rb
from Cell signaling (Beverley, MA, USA) were used for Western
blotting. Piﬁthrin-α (PFT-α) was purchased from Alexis Biochem-
icals (San Diego, CA, USA) and TNF-α was purchased from R&D
Systems (Minneapolis, MN, USA). All other chemicals were of the
highest purity commercially available.
Balloon injury in rat carotid artery
The rat carotid artery balloon-injury method was described
previously [20,21]. Rats were pretreated with vehicle or DMF (each
n¼5 per group) using gavage, 1/day for 3 days. DMF at 5 or 15mg/kg
was dissolved in DMSO/corn oil (3:7 ratio) which was used as
vehicle. After the balloon injury (BI), rats were treated with vehicle,
DMF 5mg/kg/day or 15mg/kg/day for 2 weeks continuously. At the
conclusion of the study, the tissue samples were harvested after
pentobarbital sodium injection (50mg/kg i.p.). The left common
carotid arteries were harvested and ﬁxed with 4% paraformalde-
hyde. Sections were used for hematoxylin & eosin (H&E) staining
(ScyTek Laboratories, Logan, UT, USA) and further immunohisto-
chemical staining. The representative sections in the middle of the
artery from control, BI, BIþDMF (5mg), and BIþDMF(15mg), n¼2,
3, 4, and 4, respectively, were used for the statistical analysis. IA/MA
ratio was determined as intimal area divided by medial area. IA/MA
ratios between the groups were analyzed by one way ANOVA and
nonparametric followed by Bonferroni's test. Po0.05 was consid-
ered statistically signiﬁcant.
Histological analysis
Immunohistochemical staining was performed using antibo-
dies for Ki67 (1:100 dilution, NCL-Ki67p, Novocastra Laboratories
Ltd, UK) and CD31 (1:100 dilution, MAB1393, Millipore Corpora-
tion, USA) using the method described in a previous study [20,21].
An Ultravision LP Large Volume Detection System and DAB plus
substrate system were used for signal detection according to the
manufacturer's instruction (Lab Vision, USA).
Cell culture
Primary VSMCs were isolated from thoracic aorta of 4-week-
old male SD rats [20,21]. The cells were cultured in DMEM (Low
glucose) supplemented with 10% (v/v) FBS and antibiotics (100
units/mL penicillin and 100 mg/mL streptomycin) at 37 1C in
humidiﬁed 5% CO2 incubator. Cells between the third and sixth
passage were used in all experiments. Primary human aortic
endothelial cells (HAECs) were purchased from Lonza (Walkers-
ville, MD, USA). The cells were cultured in 2% FBS endothelial
growth medium (EGM)-2 Bullet Kit (Lonza) and used for the
experiments at passages 5–10. DMF was dissolved in DMSO which
was used as vehicle.
Cell proliferation assay
Rat VSMCs were plated in 6-well culture plates at 1104 cells/
well and were grown until 30% conﬂuence. The VSMCs were
rendered quiescent by incubation for 24 h with serum-free media
followed by the stimulation with 15% FBS including vehicle or
indicated dose of DMF for the next 48 h. The cells were detached
using 0.25% Trypsin–EDTA and were counted using hematocyt-
ometer after trypan blue staining.
Cell viability assay
HAECs were seeded into 96-well culture plates at 5103 cells/
well with 0.1% FBS EGM-2 media and incubated for 24 h. The media
for the HAECs was changed to 0.1% FBS EGM-2 media including
TNF-α (50 ng/mL), vehicle or indicated dose of DMF for next 24 h.
Cell viability was measured using Cell Counting Kit-8 (Dojindo,
Rockville, MD, USA).
DNA synthesis assay
5-Bromo-20-deoxy-uridine (BrdU) labeling and detection kit III
was purchased from Roche (Mannheim, Germany). VSMCs were
seeded into 96-well culture plates at 1103 cells/well. At 30%
conﬂuence, the cells were starved with serum-free media for 48 h.
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The cells were stimulated with 15% FBS and pretreated with
vehicle or indicated dose of DMF for 24 h. Cells were incubated
with BrdU 10 mmol/L for an additional 6 h. The incorporation of
BrdU was measured according to the manufacturer's instruction.
Western blot analysis
Cells were washed with PBS and harvested by scraping in the
lysis buffer (20mmol/L Tris–HCl (pH 7.4), 1% NP-40, 5mmol/L
EDTA, 2mmol/L Na3VO4, 100mmol/L NaF, 10mmol/L Na4P2O7,
100 mmol/L PMSF, 7 mg/mL aprotinin, and 7 mg/mL leupeptin).
Proteins were separated on 10–12% SDS-polyacrylamide gel,
transferred to PVDF membranes (Millipore, USA) and subjected
to immunoblot analysis using appropriate antibodies.
Cell cycle analysis
The VSMCs were seeded at a density of 3105 cells into 100mm
culture dishes. At 30% conﬂuence, the cells were starved in serum-
free media for 48 h and stimulated with 15% FBS for 20h. Then, the
cells were trypsinized, centrifuged at 1000 rpm for 5min, washed
once with cold PBS including 1% BSA, ﬁxed in 70% cold ethanol, and
stained with 1mL of staining solution containing 50mg/mL propi-
dium iodide, 1mg/mL RNase A and 1.5% Triton X-100 for at least 1 h
in the dark at 4 1C. DNA content of the cells was analyzed by ﬂow
cytometry (FACS Calibur, BD Bioscience, San Jose, CA, USA).
Promoter assay and plasmids
The reporter plasmid p21-Luc andwas kindly provided by Dr. Xiao-
Fan Wang (Duke University Medical Center, Durham, NC, USA) and Dr.
Taeg Kyu Kwon (Keimyung University, Daegu, Rep, Korea). The
mammalian expression plasmid pcDNA3-mouse Nrf2 was a kind gift
from Dr. Carl-Henrik Heldn (Ludwig Institute for Cancer Research,
Uppsala, Sweden) and Dr. Mi-Kyoung Kwak (Yeungnam University,
Daegu, Rep, Korea). For promoter assay, AD-293 cells at 3104 cells/
well were seeded on 24-well plates, incubated for 24h, and trans-
fected with 300ng of reporter plasmids and mammalian expression
plasmids encoding Nrf2 (100 or 300ng/well) using the TransIT-LT1
transfection reagent (Mirus Bio Incorporation, Madison, WI, USA).
After 24 h, cells were harvested in lysis buffer (0.2mol/L Tris–HCl,
pH 8.0, 0.1% Triton X-100). Cytomegalovirus (CMV)-β-galactosidase
plasmids were cotransfected as an internal control. Luciferase activity
was normalized to that of β-galactosidase.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA from the cells was isolated using Trizol reagent
(Invitrogen, USA) and reverse-transcribed with the First Strand cDNA
synthesis kit (Fermentas, Lithuania) according to manufacturer’s
instructions. RT-PCR was performed using the primer sequences as
follows: (1) rat Nrf2, sense primer: 50-CCA TTT ACG GAG ACC CAC
CGC-30, antisense primer: 50-GCC CAA GTC TTG CTC CAG CTC-30;
(2) rat Keap1: sense primer: 50-TGC TCA ACC GCT TGC TGT ATG-30,
antisense primer: 50-CCA AGT GCT TCA GCA GGT ACA-30; (3) human
eNOS: sense primer: 50-CTG TGG AAA GAC AAG GCA GC-30, antisense
primer: 50-CTG TTC TTC CTG GTG ATG CC-30; (4) human Nrf2: sense
primer: 50-AGA CAA ACA TTC AAG CCG CT-30; human Nrf2: antisense
primer: 50-CCA TCT CTT GTT TGC TGC AG-30; (5) human NQO1 sense
primer: 50-TTA CTA TGG GAT GGG GTC CA-30, antisense primer: 50-TCT
CCC ATT TTT CAG GCA AC-30.
siRNA transfection
HAECs were seeded into 60mm culture dishes at a density
of 2105 cells/well and were transfected simultaneously with
human Nrf2-siRNA, human NQO1-siRNA and control siRNA duplex
(Bioneer Corporation, Daejeon, Korea) using Lipofectamine™ RNAi-
MAX according to the manufacturer's instruction. At 24 h after
transfection, the cells were incubated with 0.1% FBS media
including DMF7TNF-α for 24 h.
Preparation of recombinant adenovirus
A full length mouse Nrf2 was inserted into KpnI and XhoI sites
of the pAdTrack-CMV shuttle vector. The recombinant adenoviral
plasmid was generated as described previously [20,21] and recombi-
nant adenoviruses were ampliﬁed using HEK-293 cells and subse-
quently puriﬁed by CsCl banding.
Statistical analysis
Numerical data are represented as means 7SD or means 7SE.
Statistical analyses were performed using an unpaired Student's
t-test or one way ANOVA as appropriate and a value of Po0.05
was considered statistically signiﬁcant (GraphPad Software, Inc., La
Jolla, CA, USA).
Results
DMF prevents neointimal hyperplasia in rat carotid artery after
balloon injury
We examined the beneﬁcial effects of DMF on abnormal vascular
remodeling using a rat carotid artery balloon injury model. Neoiniti-
mal hyperplasia was observed in the vessel at 14 days after injury
(Fig. 1A). DMF signiﬁcantly reduced neointimal formation in the
injured artery in a dose-dependent manner (Fig. 1B). The expression
of Ki67, a marker of cell proliferation, was strongly increased in
neointimal formation but not in the medial area of balloon-injured
arteries at 14 days, an effect which was attenuated by DMF treatment
(Fig. 1C). These results indicate that DMF reduces neointimal hyper-
plasia induced by balloon injury in rat carotid arteries through
inhibition of abnormal VSMC proliferation.
DMF inhibits VSMC proliferation through G0/G1 phase cell cycle
arrest
Based on viable cell counting and DNA synthesis analysis for cell
proliferation rate, DMF treatment decreased cell numbers and DNA
synthesis in VSMCs signiﬁcantly (Fig. 2A and B). Cell cycle analysis
using ﬂow cytometry showed that the dramatic induction of S phase
by serum compared to quiescent cells was reduced by DMF treatment;
the cells at G0/G1 phase were increased in DMF-treated cells
compared to serum only treated cells, indicating that DMF arrests
the cells at G0/G1 phase (Fig. 2C and D). In addition, DMF signiﬁcantly
decreased serum-induced expression of cell cycle promoting proteins
such as p-Rb, cyclin D, and cyclin E which are involved in G1 to S
phase transition in VSMCs (Fig. 2E–G). Taken together, these data
suggest that DMF suppresses VSMC proliferation through the induc-
tion of G0/G1 phase cell cycle arrest.
DMF upregulates p21 protein through both p53-independent (early)
and p53-dependent (late) pathways
Because p21 and p27 repress cyclins/cyclin dependent kinase
(CDK) complexes, which play a critical role in G1 to S cell cycle
progression by increasing p-Rb, we examined the effect of DMF on
the expression of these cell-cycle inhibitory proteins. As shown in
Fig. 3A–C, DMF signiﬁcantly increased p21 and p-p53 protein level
in a time-dependent manner implying the involvements of p21
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and p53 in the growth inhibitory effect of DMF in VSMCs. Also,
DMF treatment markedly stimulated p21 promoter luciferase
activity in a dose dependent manner (Fig. 3D). Next, we deter-
mined if the p21 promoter activity induced by DMF was regulated
by PFT-α, an inhibitor of p53 transcriptional activity. The addition
of PFT-α diminished DMF-enhanced p21 promoter activity in a
dose dependent manner (Fig. 3E). Likewise, pharmacological
inhibition of p53 attenuated the growth inhibition of VSMCs by
DMF signiﬁcantly (Fig. 3F) suggesting that anti-proliferative effect
of DMF was partially mediated by p53 activity. Intriguingly, we
observed that DMF caused a very rapid increase in p21 protein
expression, which occurred earlier than p53 phosphorylation
(Fig. 3A–C). Concomitantly, p53 pharmacological inhibition had
little effect on early induction of p21 protein at 1 h after DMF
treatment, whereas it strongly inhibited p21 expression at 6 h
(Fig. 3G–J). These ﬁndings suggest that DMF inhibits VSMC pro-
liferation by upregulating p21 via p53-independent and -dependent
pathways at different time points.
Nrf2 plays an important role in the DMF-induced p21 upregulation,
independent of p53 activity
To identify the mediator of p53-independent induction of p21
proteins, we investigated the involvement of Nrf2, which has been
shown to be activated by DMF [7,8]. DMF signiﬁcantly augmented
Nrf2 protein expression in VSMCs from 30min to 12 h in a time-
dependent manner (Fig. 4A), whereas it had no effect on Nrf2
mRNA levels (data not shown). Based on immunoﬂuorescence
microscopic analysis, Nrf2 protein expression was signiﬁcantly
increased in the nucleus and the cytosol at 1 h after DMF treat-
ment (Fig. 4B). Nrf2 overexpression by adenovirus delivery
increased p21 protein, but not phosphorylated p53 protein expres-
sion (Fig. 4C). To explore the mechanism for Nrf2-induced p21
upregulation, we overexpressed Nrf2 and assessed p21 promoter
activity. Nrf2 overexpression did not activate p21 promoter activ-
ity, but it did stimulate promoter activity of NQO1, a known target
of Nrf2 (Fig. 4D). Likewise, HO-1 and NQO1, genes known as direct
targets of Nrf2, took at least 2 hours for induction, which might
not interfere with the p21 upregulation occurring within 1 h of
DMF treatment (Fig. 4E) [22,23]. Also, p21 protein expression was
unchanged by HO-1 inhibition with tin protoporphyrin (SnPP), an
inhibitor of HO-1 activity, or by NQO1 inhibition with ES936, an
inhibitor of NQO1 activity (Fig. 4F and G). Additional quantitative
analyses for Fig. 4A–G are shown in Supplemental Fig. 1.
Increased Nrf2 activity suppressed serum-induced VSMC prolif-
eration signiﬁcantly (Fig. 4H). To verify the requirement of Nrf2
for DMF-induced p21 expression, we assessed the effect of
adenovirus overexpressing Keap1 (Ad-Keap1), a negative regu-
lator of Nrf2. As shown in Fig. 4 I and J, Keap1 overexpression
markedly down-regulated DMF-induced p21 protein levels at 1 h
after DMF treatment, suggesting that Nrf2 activity plays an
important role in regulation of p21 protein by DMF, independent
of NQO1 activity.
DMF accelerates vascular re-endothelialization by ameliorating
endothelial cell dysfunction induced by TNF-α
To explore the prospective effects of DMF on vascular re-endothe-
lialization, we examined the effect of DMF on CD31 expression, a
speciﬁc maker of endothelial cells, using immunohistochemical
analysis in rat carotid artery after balloon injury. In Fig. 5A, DMF
reversed the decrease in CD31 expression in carotid artery after
balloon injury. Although we assessed the effect of DMF on HAEC
proliferation, we did not observe any inhibitory effect of DMF on the
proliferation of HAEC or any change in expression of cell cycle
proteins (Fig. 5B and C). Previous studies demonstrated that TNF-α
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Fig. 1. Dimethylfumarate inhibits balloon injury induced neointimal hyperplasia in rat carotid arteries. (A) Representative histological cross-sections using H&E staining from
uninjured, and neointimal formation after balloon injury in carotid arteries from rats orally given either vehicle or indicated concentrations of DMF (100 ), scale bar (100 mm).
(B) Morphometric analysis based on computerized image system for the carotid arteries from 4 different rat groups (n¼2, 3, 4, and 4). Bars represent the mean7SE. nPo0.05 vs.
uninjured group, †Po0.05 vs. balloon injured group treated with vehicle. The statistical analyses were performed by Bonterroni's test. (C) Immunohistochemical staining for Ki67
antigen, a proliferation marker. Arrows indicate Ki67-positive cells (shown in brown) during neointimal formation after balloon injury (200 ), scale bar (100 mm).
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blockade accelerated functional endothelial recovery after balloon
angioplasty [13,14]. So, we conﬁrmed that TNF-α-induces endothelial
cell dysfunction by assaying for eNOS expression, which was sig-
niﬁcantly improved by DMF (Fig. 5D). Additionally, we showed that
Nrf2–NQO1 expression mediated the beneﬁcial effect of DMF on
endothelial cells (Fig. 5E–H). Overall, DMF regulates eNOS expression
mediated by Nrf2–NQO1 activity, which can improve vascular func-
tion and re-endothelialization after vascular injury in vivo.
DMF protects against endothelial cell apoptosis induced by TNF-α
mediated by Nrf2–NQO1 axis
To explain the stimulatory effect of DMF on re-endothelializa-
tion, we also investigated whether DMF could inhibit apoptosis
of endothelial cells induced by TNF-α [24]. As expected, DMF
protected endothelial cells from TNF-α induced apoptosis in a
dose-dependent manner (Fig. 6A). Consistent with Fig. 6A, after
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C.J. Oh et al. / Redox Biology 2 (2014) 855–864 859
Nrf2 or NQO1 knockdown, DMF failed to prevent TNF-α induced
cell apoptosis (Fig. 6B and C). Also, morphological data by micro-
scopy showed that DMF increased low cell density affected
by TNF-α, which was attenuated with siRNA for Nrf2 or NQO1 in
HAECs (Fig. 6D). In general, enhanced Nrf2 or NQO1 activity by DMF
can decrease the apoptosis of endothelial cells induced by TNF-α.
Discussion
In the present study, we demonstrated that DMF inhibited the
proliferation of VSMCs via induction of G1 phase arrest leading to the
suppression of neointimal formation caused by balloon injury in vivo.
This protective effect of DMF against neointimal hyperplasia was
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dependent on the cooperative induction of p21 by activation of Nrf2
and p53 activity. Likewise, we observed that DMF treatment acceler-
ated re-endothelialization after balloon injury in vivo and DMF
protected the endothelial cell from TNF-α-induced apoptosis via
Nrf2–NQO1 activity. Excessive proliferation of VSMCs is a primary
source of vascular restenosis after PTCA [1]; therefore, new drug
development and better understanding of the molecular mechanisms
are very important for treating patients. Originally, DMF was used as
an anti-psoriatic ointment and orally for the treatment of multiple
sclerosis, inﬂammatory skin disease and several cancers [25,26]. In this
study, we found that DMF could inhibit VSMCs proliferation through
p21 induction which led to G1 cell cycle arrest. We veriﬁed that p21
protein expression was upregulated by DMF, mediated by both p53-
independent (early) and p53-dependent (late) pathways. Initially, DMF
increases p21 protein stability via stimulated Nrf2 activity. Overall,
p21 expression was regulated by DMF by actions on both protein
stability (p53-independent pathway) and transcription (p53-depen-
dent pathway).
Even though inhibition of abnormal VSMCs proliferation has been
a primary target to prevent neointimal hyperplasia after PTCA,
delayed re-endothelialization contributes to the acceleration of
neointimal hyperplasia. It is well accepted that apoptosis, impaired
re-endothelialization, and vascular endothelial cell dysfunction play
important roles in the development of atherosclerosis and restenosis
[27]. In the case of DMF, previous studies have shown that DMF
inhibited TNF-α-induced expression of inﬂammation markers such
as VCAM-1 and ICAM-1 via inhibition of NF-κB signaling [28,29] and
attenuated TNF-α-induced tissue factor expression in endothelial cells
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[12], indicating that DMF might inhibit VSMC migration and throm-
bosis after balloon angioplasty. Also, DMF protected against TNF-α-
induced endothelial cell apoptosis and dysfunction such as reduced
eNOS expression via Nrf2–NQO1 activity in our study. Previous studies
have shown that TNF-α induces endothelial cell apoptosis, while it
increases the proliferation of VSMCs [24,30]. Taken together, DMF
might be used as a therapeutic drug for vascular diseases including
atherosclerosis and PTCA-associated restenosis.
HO-1 and NQO1 are well-known target genes stimulated by Nrf2.
The by-products of HO-1 (hemin and carbon monoxide) have been
reported to inhibit proliferation and induce apoptosis of VSMCs [31].
Previously, we showed that β-lapachone inhibited proliferation of
VSMCs by activating NQO1 [22]. Thus, we examined the involvement
of HO-1 or NQO1 on DMF-induced p21 expression and inhibition of
VSMC proliferation. HO-1 and NQO1 proteins were not detected clearly
until 2 h after DMF treatment, in contrast to p21 induction which was
detectable at an early time. Similarly, the inhibition of HO-1 by SnPP
and NQO1 activities by ES936 did not have any considerable inhibitory
effect on DMF-induced p21 expression, implying that HO-1 and NQO1
activities were not required for p21 induction by DMF. DMF failed to
reverse TNF-α-induced apoptosis and inhibition of eNOS expression in
endothelial cells after knockdown of NQO1. Thus, NQO1 may be a
crucial factor in the survival and function of vascular endothelial cells.
Collectively, our data suggest that DMF may protect against restenosis
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after balloon angioplasty or stenting by inhibiting neointimal hyper-
plasia and by accelerating re-endothelialization by blocking the
apoptosis and dysfunction of endothelial cells induced by TNF-α.
Conclusion
Vascular remodeling after balloon injury can be ameliorated by
DMF via 2 distinct mechanisms in VSMCs and endothelial cells,
respectively. Firstly, DMF stimulates Nrf2 activity leading to p21
upregulation, which blocks the G1 to S phase transition in cell cycle
immediately, independent of p53 activity. Later on, p21 expression can
be regulated by enhanced p53 transcriptional activity in VSMCs. The
other mechanism accounting for the beneﬁcial effect by DMF on
vascular injury may be explained by a protective role on endothelial
apoptosis and eNOS expression followed by accelerated re-
endothelization via Nrf2–NQO1 activity. Therefore, these results sug-
gest that DMF could be a useful therapeutic for patients with vascular
restenosis.
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